A positive outcome from a Cologuard screening suggests the presence of altered DNA or blood in the stool sample, potentially indicating colorectal cancer or precancerous polyps. For example, the test may detect DNA mutations associated with colon cancer or hemoglobin, a protein found in blood. This does not definitively diagnose cancer, but rather signals the need for further evaluation, typically a colonoscopy.
Early detection of colorectal cancer is critical for successful treatment, and this non-invasive screening offers a convenient alternative for individuals at average risk who may be hesitant about a colonoscopy. By identifying potential problems before noticeable symptoms arise, it allows for timely intervention, potentially preventing cancer development or catching it at an earlier, more treatable stage. This screening approach has expanded access to vital early detection measures, contributing significantly to public health efforts focused on reducing colorectal cancer mortality.
